SVB Securities Reaffirms Their Buy Rating on PepGen Inc. (PEPG)

SVB Securities analyst Joseph Schwartz reiterated a Buy rating on PepGen Inc. (PEPGResearch Report) on December 7. The company’s shares closed yesterday at $13.91.

According to TipRanks, Schwartz is an analyst with an average return of -18.4% and a 32.76% success rate. Schwartz covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical, Ascendis Pharma, and Amicus.

The analyst consensus on PepGen Inc. is currently a Moderate Buy rating.

See Insiders’ Hot Stocks on TipRanks >>

The company has a one-year high of $17.81 and a one-year low of $4.32. Currently, PepGen Inc. has an average volume of 302K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics with the goal of transforming the treatment of severe neuromuscular and neurologic diseases.

Read More on PEPG:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More